The analysis revealed that individuals with a smaller temporalis CSA exhibited a significantly higher likelihood of developing Alzheimer's dementia. Furthermore, those with reduced muscle mass ...
Exegenesis Bio, a clinical stage global gene therapy company is pleased to announce that US FDA has granted Orphan Drug Designation ("ODD") to EXG110, a novel gene therapy for Fabry disease, a rare ...
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, ...